

#### **Defense Health Board**

#### Vaccine Safety and Effectiveness Working Group Report

Gregory A. Poland, MD President, Defense Health Board





- DoD request to form a Work Group with the following objectives:
  - Discuss DoD post-licensure vaccine safety, effectiveness, and surveillance studies
  - Review and discussion of published and unpublished data from DoD research of vaccines in use by DoD
  - Discuss future vaccine safety, effectiveness, and surveillance studies within DoD
  - Focus on FDA-approved vaccines
  - Work group to provide guidance and advice on what studies should be done, priorities, identify research gaps, and areas of research which should be developed





- DHB attendees:
  - G. Poland
  - E. Kaplan
  - J. Silva
  - M. Miller
  - D. Walker
- USUHS
- 2 June 2008



## Background

- Briefings
  - Col. Randy Anderson (MILVAX)
  - Dr. Tyler Smith (DHRC)
  - Col. Phil Pitman (Vaccine Clinical Research Center – USAMRIID)
  - Dr. Angelia Eick (AFHSC)
  - CDR. Kevin Russell (NHRC)
  - Col. Renata Engler (VHC)





• ✓ Little/no progress

- Some progress
- ✓ Significant progress



### **Specific Issues**

- Enhanced interactions, coordination, and collaborative efforts across DoD with respect to vaccine surveillance
- External validation of vaccine research initiatives
- Anthrax, smallpox, influenza vaccines
  - Recipient concern re: long-term safety, reproduction, hospitalization, etc.
  - Reproductive health (need for cross-specialty, interdisciplinary research)
  - ACAM 2000
  - Adenovirus vaccine



#### AFEB 1999

- DoD-Wide Review of Vaccine Policy and Procedures
  - Multiple meetings
  - Outside contractor
  - Published monograph
  - Resulted in a series of 12 major recommendations



- Urgently recommend that policies and practices that insure the ready supply to the military of vaccines essential to the mission be developed
  - Assign "watchdog" organizations within DoD
  - Provide funding for collaborative projects and development of strategically important vaccines that have limited markets
  - ? DoD-owned manufacturing facility

#### ✓ Some progress

- Military Vaccine (MILVAX) Agency and OASD(HA) monitor supply situation, engage other DoD entities as needed. Adenovirus vaccine project funded and well underway
- New vaccine development inadequately funded and slow. DoD-owned manufacturing facility not implemented beyond WRAIR pilot plant.



- DoD further develop and expand efforts towards standardized computerized record-keeping and tracking of all administered vaccines to all persons (AD, reserve, beneficiaries, etc.)
  - Include ability to rapidly access information
  - Standardized across services and facilities
- Substantial progress
- ✓ Work remaining:
- Upgrade USN shipboard system for consistent synchronization with shorebased systems
- Enhance ability to track family members and retiree
- Enhance ability to exchange electronic immunization records
- Enhance ability to give retirees and separated personnel access to their immunization records



- Each service measure and report up-todate immunization rates as key indicators of medical care delivery and force readiness
- ✓ Some progress
- Immunization rates as indicators of troop readiness available and tracked
- Work remaining: Immunization rates of communities based on age or underlying risk factors insufficiently developed or implemented



- Consider the concept of a "Vaccine and Immunobiologics Oversight Board"
  - Increase involvement of Reserves and National Guard in the planning and implementation of immunization programs
- ✓ Achieved.
- MILVAX Agency (previously the AVIP Agency from 1998 to 2002) performing admirable job in synchronizing and coordinating programs among the Armed Services (including Active, Reserve, and Guard).



- DoD should develop and disseminate, as soon as practical, a new Joint Instruction
  - Address policy for use of IND vaccines
  - Policy for introducing new vaccines
  - Obtaining informed consent
  - Revise record-keeping requirements
  - Reduce differences between services
  - Address issue of screening for immunity
- Achieved. US Army Regulation 40-562; Navy Bureau of Medicine & Surgery Instruction 6230.15A; Air Force Joint Instruction 48-110; Coast Guard Commandant Instruction M6230.4F. Immunizations and Chemoprophylaxis. 2006(Sep 29):1-31.
  www.apd.army.mil/pdffiles/r40\_562.pdf
- ✓ Great success with USAF and US Army screening of basic trainees for pre-existing immunities. USN should emulate. Status for USMC, USCG?



- Address whether current procedures and resources are sufficient to insure appropriate personnel are aware of current official policy
  - Develop a web page or other communication devices
- Substantial progress. Extensive data and resources available at www.vaccines.mil, www.anthrax.mil, www.smallpox.mil, 877-GET-VACC, email, and other communications media.
- Work remaining: Ongoing effort to educate providers, medics, troops, families.



- DoD commit to full informing every service member of the health risks, personal and military benefits, and proper use of all vaccines and other medical countermeasures
  - Develop risk communication materials
  - Provide VIS
  - Off-label use policies
  - Risk communication research
- Substantial progress. Extensive information at www.vaccines.mil and other sources.
- Work remaining: Availability of VIS, perhaps as posters?



- DoD should address issues of standardized training and proficiency of immunization delivery practice
  - Training and licensure requirements
  - Ongoing proficiency standards and continuing medical education
  - Address credentialing and licensing
  - Better define the above issues in the Joint Instruction
- Substantial progress. Immunization University represents a novel and creative effort to disseminate training across continents and time zones. The CQIP quality-improvement tool sets precedent and raises the bar for civilian settings.
- Work remaining: DoD should expand the training effort to reach 100% of immunizers and adopt/enforce explicit criteria for training. Consolidation of enlisted medic training offers another opportunity for increased standardization.



 DoD develop a vaccine policy and practice statement for the use of vaccines and immunobiologics in humanitarian missions

X Little/no progress



- Recommend maintaining the current centralized DSCP procurement system, while providing flexibility at the local level with the many other adjunct procurement systems
- Centralized procurement of influenza, anthrax, and smallpox vaccines.
- ✓ Decentralized procurement of other vaccines along commercial "prime vendor" model.



- Recommend DoD continue to participate in the development of a comprehensive Pandemic Influenza Planning document and devise, disseminate and test a DoDwide plan
- Substantial progress. DoD has been an active and energetic partner in the national influenza pandemic planning process.
- Work remaining: Consider value of stockpiling vaccines and antibiotics to prevent secondary bacterial infections (recognizing high rate of troop deaths in 1918).



- Review of vaccine policy, practice and use recommendations every 2-3 years
- Now is a good time to begin a systematic review of the 2006 Joint Regulation/Instruction, training requirements, and other needs identified by the present discussion.



## Overall Assessment Since 1999

- Overall letter grade A
- DoD has made *substantial* progress in virtually ALL areas identified in the 1999 DoD-wide review
- Opportunities:
  - Enhance DoD electronic immunization tracking
  - Develop a humanitarian vaccine policy
  - Insure availability of all vaccines (adenovirus example)
  - Vaccinator certification



### Next Steps

- Further Meetings
  - Anticipate 2-3 meetings per year
  - First meeting was introductory and provided background material
  - Next Steps involve:
    - Agendas specific to particular vaccines (anthrax, smallpox in particular)
    - Overall coordination and management of vaccine surveillance efforts



# DISCUSSION



#### **BACK UP SLIDES**

